Group 1 - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between -39.85 million and -26.79 million RMB, representing a decrease of 174.56 million to 187.62 million RMB compared to the previous year, a year-on-year decline of 118.13% to 126.97% [1] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses for 2025 is projected to be between -68.73 million and -45.82 million RMB, reflecting a decrease of 171.21 million to 194.12 million RMB compared to the previous year, a year-on-year decline of 136.54% to 154.82% [1] Group 2 - The CRO industry is experiencing downward pressure on overall sales order prices due to changes in the macro environment and intensified industry competition, leading to a decline in the company's main business gross margin [2] - The company signed new orders amounting to 1.135 billion RMB for the year, an increase of 38.62% year-on-year, with overseas market new orders amounting to 74.77 million RMB [2] - The company is enhancing its overseas market expansion efforts through diversified channels and regional layouts, which is expected to increase the proportion of overseas revenue and support revenue growth [2] - As of the end of 2025, the company's backlog of orders reached 1.248 billion RMB, an increase of 28.23% compared to the end of 2024, laying a solid foundation for future operational development [2]

Group 1 - The core viewpoint of the article is that Yinos (688710.SH) is planning to acquire a controlling stake in Yilinsi to enhance its integrated service solutions in the biopharmaceutical non-clinical research sector [1][2] - The acquisition aims to improve the company's upstream and downstream industry chain layout, establishing a comprehensive service system that covers drug research from early concept validation to industrial incubation [1][2] - Yilinsi, established in February 2004, specializes in clinical trial services, focusing on phases I to IV of new drug clinical trials, pharmacokinetics research, and various clinical trial management services [1][2] Group 2 - This transaction is a strategic move in response to national policies encouraging mergers and acquisitions among listed companies to enhance their core business and industry chain [2] - The acquisition will extend the company's business chain, enhance service segments, and strengthen collaboration among different business units, thereby improving the overall quality of development [2] - Yilinsi is a high-tech enterprise and has a mature system and professional capabilities in the clinical research service field, which will significantly enhance the company's comprehensive service capabilities and competitive edge in the industry [2]

Core Viewpoint - The company is experiencing a decline in net profit and gross margin due to macroeconomic changes and intensified industry competition, but it is focusing on expanding its domestic and international business to drive high-quality growth in core operations. Company Performance - The company's main business includes early-stage drug evaluation, non-clinical research, and clinical testing and translational research [9] - The net profit attributable to shareholders and the net profit after deducting non-recurring gains and losses decreased compared to the same period last year [9] - In 2025, the company signed new orders worth RMB 1.135 billion, a year-on-year increase of 38.62%, with overseas orders amounting to RMB 74.772 million [9] - By the end of 2025, the company's backlog of orders reached RMB 1.248 billion, an increase of 28.23% from the end of 2024 [9] Industry Context - The CRO industry is facing downward pressure on sales order prices due to changes in the macro environment and increased competition [9] - The overall sales performance in the industry is being impacted, leading to a decline in gross margins for companies within the sector [9]

证券之星消息，益诺思发布业绩预告，预计2025年全年归属净利润亏损2678.89万元至3984.86万元。 公告中解释本次业绩变动的原因为： 益诺思2025年三季报显示，前三季度公司主营收入5.71亿元，同比下降35.33%；归母净利润-1478.81万 元，同比下降111.14%；扣非净利润-3475.94万元，同比下降128.8%；其中2025年第三季度，公司单季 度主营收入1.95亿元，同比下降29.39%；单季度归母净利润40.15万元，同比下降98.92%；单季度扣非 净利润-220.28万元，同比下降107.06%；负债率25.17%，财务费用-587.79万元，毛利率28.34%。 受前期宏观环境变化因素影响及行业竞争加剧的叠加影响，CRO 行业整体销售订单价格承压下行，公 司的主营业务毛利率同比下降，报告期内公司归属于上市公司股东的净利润以及归属于上市公司股东扣 除非经常性损益后的净利润较上年同期出现下滑。 2025 年度，公司加大国内外业务布局力度，通过多维举措驱动核心业务高质量发展。公司全年新签订 单金额为人民币 11.35 亿元，同比上涨 38.62%，其中海外市场新签订单金额为人民币 ...

2025年上半年，朗研生命营收仅2.31亿元。 作者丨孙梦圆 姚悦 编辑丨于婞 来源 | 野马财经 阳光诺和(688621.SH)的收购计划再度告吹。 1月27日晚，"CRO龙头企业"阳光诺和宣布，终止对江苏朗研生命科技控股有限公司(下称"朗研生 命")100%股权的收购。这项自2025年4月披露、11月获受理的交易，在推进两个多月后戛然而止。公司 解释称，终止原因是基于当前市场环境的变化，为维护公司及股东利益而做出的审慎决定。 事实上，这已经是阳光诺和第二次收购朗研生命失败了。 中国城市专家智库委员会常务副秘书长林先平表示，两次收购失败可能暴露战略协同评估不足或风险预 案缺失。CRO行业高度依赖研发稳定性和规模效应，并购需更严谨的战略匹配度分析，避免过度依赖 关联扩张。企业应深入评估标的业务可持续性，并设计灵活的交易结构以应对市场变化。 截至1月30日收盘，阳光诺和报收64.92元/股，总市值72.71亿元。 图源：罐头图库 01 两度筹划两度终止 阳光诺和第一次筹划收购朗研生命，从2022年就开始了。 作为药物"临床前+临床"CRO(医药研发合同外包服务机构)综合服务商，阳光诺和一直想通过收购朗研 生命， ...

大摩又指，集团管理层对行业前景保持乐观，而近期的一次会议上，管理层提到中国CRO行业似乎正 处于复苏态势。 摩根士丹利表示，强劲的盈利增长主要归因于泰格医药资产的大幅重估，以及2024年相对较低的基数。 尽管受订单取消及收款困难影响，集团经常性收益表现疲软，但公司新订单增长依然强劲。扣除取消订 单后的新增在手订单净额介于95亿元至105亿元，同比增长13%至25%。 智通财经APP获悉，摩根士丹利发布研报称，泰格医药(03347)公布2025年初步业绩，营收介乎为66.6亿 元至76.8亿元人民币(下同)，同比增长1%至16%。该范围较摩根士丹利预估为低2%至高12%。净利润介 乎8.3亿元至12.3亿元，同比增长105%至增长204%。予泰格医药(300347.SZ)A股目标价81元，评级"增 持"。 ...

2026年1月27日， 阳光诺和 （688621.SH）发布公告，宣布正式终止以发行股份及可转换公司债券方式收 购朗研生命100%股权的重组计划，并撤回相关申请文件。这是自2022年以来，阳光诺和第二次对同一标 的发起收购并以失败告终。至此，该项目也成为 国联民生 证券今年以来已终止的第三个项目。 值得注意的是，两次交易，相隔三年，标的相同、实控人一致、中介机构未变——国联民生证券始终担任 独立财务顾问（其中第一次为合并前的民生证券）。从2022年16.11亿元的首次尝试，到2025年12亿元的 再度推进，阳光诺和始终试图打通"CRO（研发外包）+医药工业"一体化平台的战略构想，屡次在政策变 化与估值博弈的双重压力下受阻。 | 项目 | 第一次收购（2022–2023） | 第二次收购 (2025-2026) | | --- | --- | --- | | 交易对价 | 16.11亿元 | 12亿元 | | 标的估值依据 | 2022年收益法评估 | 2025年6月30日收益法评估 | | 核心产品风险 | 缅沙坦类、蚓激酶等集采降价 | 同类产品续标价降幅超90% | | 业绩承诺 | 未明确披露 | 20 ...

第一：贵金属继续大涨 连续震荡几天后，终于获得了足够的推动了，继续上涨。上场吗？ 对我来说，这不是选择题，因为看不懂的地方，根本不用思考，继续等待就可以。 据圈友所说，现在很多平时不炒股、开了户放着的朋友都开始炒起股来了。别人贪婪了，我们要恐惧吗？ 据说2005年、2015年都发生过类似的情况，这次呢？我也不知道。但我知道，自己看不懂、看不透、无法理解核心技术的行业，我是赚不到钱的。 板块上： 第二：CRO大跌 之前准备做CRO的时候，没有等来合适的机会，结果错过了一大波大涨。 我也没着急追上去，继续等待下一次的机会，这不，机会又来了。这个市场根本不缺机会，只要你有足够的耐心和金钱。 第三：中药还是不行 昨晚，中药龙头片出来维护股价，提出未来半年内，将出3亿至5亿用于增持。 结果今天仅仅一个高开，然后又是大步下跌，这谁能受得了。业绩不好，看不到前景，这是最难的。 不着急搞大仓位。 我是李聪，10年读书会主理人，活到老、学到老，关注我，一起向上成长！ 以上仅为个人看法，不作为任何建议！ 隔夜的黄金、白银继续创下新高，黄金涨破5100美金/盎司，白银突破110美金/盎司，均是历史首次。 对应的，美元指数却跌到了4 ...

Summary of the Conference Call on the CRO Industry Industry Overview - The CRO (Contract Research Organization) industry is experiencing a significant improvement in service prices and demand in Q4 2026, reversing the low price and high volume situation seen in the first three quarters of the year, indicating a recovery in the industry's fundamentals [1][5] - The procurement price for experimental monkeys has risen to around 150,000 yuan, with expectations for continued increases in 2026 due to strong global demand and supply shortages [1][6] Key Insights and Arguments - The overall performance of the CRO industry in 2026 is positive, with a notable increase in service prices and demand in Q4, following a challenging first half of the year [2][5] - The demand for overseas CRO services has been strong and is expected to accelerate, driven by improvements in the investment environment and the development of new business pipelines [4][10] - The acquisition of a monkey breeding facility in Cambodia by Charles River may lead to changes in U.S. import policies, potentially exacerbating global supply shortages and increasing procurement costs for experimental monkeys [7] Price Recovery and Market Dynamics - The CRO sector's price recovery in Q4 2026 is primarily driven by the independent and clinical segments, with the former benefiting from new drug development cycles and the latter seeing price increases due to a reduction in the number of CRO companies, which has improved the competitive landscape [1][8] - The clinical pre-stage is driven by improved demand, while the clinical stage is focused on price recovery, with expectations for continued demand growth into 2027 [9] Additional Important Points - The FDA's proposal for organoid alternatives to monkeys is expected to have limited short-term impact on demand, as global demand for monkeys remains high [6] - The overall investment environment for the CRO industry is expected to improve, with emerging business pipelines and optimized competition driving growth opportunities [4][13] - The impact of the biobusiness safety bill on the industry remains uncertain, with potential implications for multinational corporations depending on how the policy evolves [12]

Core Viewpoint - *ST Bio (000504) expects significant revenue growth in 2025, projecting operating income between 385 million to 425 million yuan, compared to approximately 130 million yuan in the previous year, indicating a substantial year-on-year increase [2][5]. Financial Performance - The company anticipates a total profit of 18.5 million to 26.5 million yuan for 2025, with net profit attributable to shareholders expected to be between 28.5 million to 32.5 million yuan, and net profit after deducting non-recurring gains and losses projected at 8.5 million to 12.5 million yuan, all indicating a turnaround from previous losses [2][5]. - Basic earnings per share are forecasted to be between 0.025 yuan and 0.037 yuan, a recovery from a loss of 0.06 yuan per share in the previous year [5]. Revenue Drivers - The revenue increase is attributed to the acquisition of Loudi Jinhong New Materials Co., which enhanced the company's recycling business, particularly in the areas of waste battery and scrap steel recycling [5][6]. - The company has also expanded sales of related products in its main business, including beauty and health products linked to its biopharmaceutical operations, contributing to revenue and profit growth [5][6]. Cost Management - In 2025, *ST Bio implemented cost reduction and efficiency improvement measures, including organizational restructuring, personnel optimization, and expense control, which enhanced profitability [6]. Regulatory Context - 2025 is a critical year for *ST Bio to avoid delisting, as the company faced a risk warning due to negative profits and revenue below 300 million yuan in 2024 [7]. - The company can apply to lift the delisting risk warning if it meets specific financial criteria in the subsequent annual report [7]. Asset Restructuring - Concurrently, *ST Bio announced the termination of a major asset restructuring plan aimed at acquiring a 51% stake in Hunan Huize Biopharmaceutical Technology Co., a professional CRO company [11][12].